Cancer Discov. 2018 Aug;8(8):907-908. doi: 10.1158/2159-8290.CD-NB2018-087. Epub 2018 Jun 28.
Three years after taking majority control of Foundation Medicine, the Swiss pharmaceutical company Roche agreed to pay $2.4 billion for the remainder of the cancer-focused genetic testing company.
在对Foundation Medicine取得多数控制权三年后,瑞士制药公司罗氏同意以24亿美元收购这家专注于癌症的基因检测公司的剩余股份。